BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp. has commenced a Phase 1/2 clinical trial to evaluate the efficacy and safety of its novel Bria-OTS™ immunotherapy for patients with advanced metastatic breast cancer. This treatment, which is designed to be personalized yet off-the-shelf, aims to provide a significant quality of life improvement and potentially extend life expectancy for patients who have undergone extensive previous treatments. Bria-OTS™, which has garnered multiple patents and is supported by clinical data, represents a groundbreaking advance in BriaCell’s cancer care portfolio.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
